Low Incidence of Corticosteroid-associated Adverse Events on Long-term Exposure to Low-dose Prednisone Given with Abiraterone Acetate to Patients with Metastatic Castration-resistant Prostate Cancer
Antineoplastic Agents, Hormonal
Antineoplastic Combined Chemotherapy Protocols
Bone Density Conservation Agents
Prostatic Neoplasms, Castration-Resistant
Steroid Synthesis Inhibitors
We assessed adverse events in patients with metastatic castration-resistant prostate cancer during long-term treatment with a low dose of a corticosteroid. We found that long-term treatment with this low-dose corticosteroid is safe and tolerable.